• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    11/14/24 3:30:56 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care
    Get the next $STVN alert in real time by email
    SC 13G/A 1 d855737dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Stevanato Group S.p.A.

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    T9224W109

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. T9224W109    SCHEDULE 13G    Page 2 of 5

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stevanato Holding S.r.l.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Republic of Italy

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     223,293,976 (1)

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     223,293,976 (1)

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     223,293,976 (1)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     81.8% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     HC

     

    (1)

    Reflects 223,293,976 ordinary shares (“Ordinary Shares”) of Stevanato Group S.p.A. (the “Issuer”) issuable upon conversion of 223,293,976 Class A ordinary shares (“Class A Ordinary Shares”) of the Issuer held by Stevanato Holding S.r.l. (the “Reporting Person”). Class A Ordinary Shares are convertible into Ordinary Shares at the option of the holder on a one-for-one basis.

    (2)

    The percentage ownership is calculated based upon 49,604,649 Ordinary Shares outstanding and takes into account the 223,293,976 Ordinary Shares issuable to the Reporting Person upon the conversion of the 223,293,976 Class A Ordinary Shares held by the Reporting Person.


    CUSIP No. T9224W109    SCHEDULE 13G    Page 3 of 5

     

    Item 1(a)

    Name of Issuer:

    Stevanato Group S.p.A.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    Via Molinella 17

    35017 Piombino Dese – Padua

    Italy

     

    Item 2(a).

    Name of Person Filing:

    This amendment no. 1 to Schedule 13G is being filed on behalf of Stevanato Holding S.r.l., an Italian limited liability company

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    Via Molinella 17

    35017 Piombino Dese – Padua

    Italy

     

    Item 2(c).

    Citizenship:

    Republic of Italy

     

    Item 2(d).

    Titles of Classes of Securities:

    Ordinary Shares

     

    Item 2(e).

    CUSIP Number:

    T9224W109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

     

    Item 4.

    Ownership

    The information required by Items 4(a) – (c) of Schedule 13G is set forth in Rows 5 through 11 of the cover page for the Reporting Person and is incorporated herein by reference.


    CUSIP No. T9224W109    SCHEDULE 13G    Page 4 of 5

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not Applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    Not Applicable.


    CUSIP No. T9224W109    SCHEDULE 13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    Stevanato Holding S.r.l.
    By:   /s/ Franco Stevanato
      Name:   Franco Stevanato
      Title:   Chief Executive Officer
    Get the next $STVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STVN

    DatePrice TargetRatingAnalyst
    12/2/2025$24.00Equal-Weight
    Morgan Stanley
    12/13/2024$28.00Outperform
    Wolfe Research
    12/3/2024$23.00Equal-Weight
    Morgan Stanley
    4/22/2024Outperform
    Exane BNP Paribas
    11/1/2023$39.00 → $29.00Buy → Hold
    Jefferies
    9/26/2023$33.00Overweight
    Stephens
    9/19/2023Market Outperform
    CJS Securities
    8/24/2023$34.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $STVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Participate in Upcoming Investor Conferences

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

    10/31/25 7:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $24.00

    12/2/25 8:34:50 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Stevanato Group S.p.A. with a new price target

    Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00

    12/13/24 8:24:13 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00

    12/3/24 8:38:45 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    12/3/25 2:38:08 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/18/25 4:00:03 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/6/25 4:10:20 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Leadership Updates

    Live Leadership Updates

    View All

    Stevanato Group Announces Results of Annual General Meeting

    -All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

    5/24/24 4:10:00 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group appoints Ugo Gay as Chief Operations Officer

    Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

    4/4/24 8:00:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Appoints Riccardo Butta as President, Americas

    The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

    2/2/22 8:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Financials

    Live finance-specific insights

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

    Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar

    8/5/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 4:06:28 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 3:30:56 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Stevanato Group S.p.A.

    SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 1:28:35 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care